<DOC>
	<DOCNO>NCT00267748</DOCNO>
	<brief_summary>This trial two part . The purpose first part trial determine dose 2 drug , sunitinib malate interferon alfa-2b , give safely combination . This part currently close enrollment . The purpose second part trial see sunitinib malate give 4/2 schedule ( 4 week treatment , 2 week treatment cycle ) well delay progression renal cell cancer sunitinib malate give continuous dose schedule . The trial also determine number patient whose cancer respond treatment , whether life patient extend , side effect treatment , bothersome disease treatment-related symptom patient , whether test find predict patient may may respond treatment future .</brief_summary>
	<brief_title>Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Advanced renal cell carcinoma clear cell origin component clear cell histology . Measurable disease Prior systemic therapy kind advance renal cell cancer History brain metastasis Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>